The Effect of Daily Methylsulfonylmethane (MSM) Consumption on High-Density Lipoprotein Cholesterol in Healthy Overweight and Obese Adults: A Randomized Controlled Trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2021 Oct 15;13(10):3620.

doi: 10.3390/nu13103620.

Affiliations

Randomized Controlled Trial

The Effect of Daily Methylsulfonylmethane (MSM) Consumption on High-Density Lipoprotein Cholesterol in Healthy Overweight and Obese Adults: A Randomized Controlled Trial

Lindsey Miller et al. Nutrients. 2021.

Abstract

Interventions to decrease inflammation and improve metabolic function hold promise for the prevention of obesity-related diseases. Methylsulfonylmethane (MSM) is a naturally occurring compound that demonstrates antioxidant and anti-inflammatory effects. Improvements in measures of metabolic health have been observed in mouse models of obesity and diabetes following MSM treatment. However, the effects of MSM on obesity-related diseases in humans have not been investigated. Therefore, the purpose of this investigation was to determine whether MSM supplementation improves cardiometabolic health, and markers of inflammation and oxidative status. A randomized, double-blind, placebo-controlled design was utilized with a total of 22 overweight or obese adults completing the study. Participants received either a placebo (white rice flour) or 3 g MSM daily for 16 weeks. Measurements occurred at baseline and after 4, 8, and 16 weeks. Outcome measures included fasting glucose, insulin, blood lipids, blood pressure, body composition, metabolic rate, and markers of inflammation and oxidative status. The primary finding of this work shows that high-density lipoprotein cholesterol was elevated at 8 and 16 weeks of daily MSM consumption compared to baseline, (p = 0.008, p = 0.013). Our findings indicate that MSM supplementation may improve the cholesterol profile by resulting in higher levels of high-density lipoprotein cholesterol.

Keywords: cardiometabolic; inflammation; methylsulfonylmethane; obesity; overweight.

PubMed Disclaimer

Conflict of interest statement

The study was funded, in part, by Bergstrom Nutrition, manufacturer and provider of OptiMSM®. The funders took no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1

Figure 1

Flow diagram of participant recruitment process. BMI, body mass index; MSM, methylsulfonylmethane.

Figure 2

Figure 2

Serum MSM concentrations were significantly elevated after 4 weeks of supplementation in the MSM group. MSM was undetectable in serum samples from placebo at each time point. * Indicates significantly different from baseline, p ≤ 0.001.

Figure 3

Figure 3

High-density lipoprotein cholesterol (HDL) was elevated at 8 and 16 weeks in the MSM group. (A) absolute values of HDL, (B) Differences from baseline. * Indicates different from baseline, p ≤ 0.05.

Figure 4

Figure 4

C-reactive protein (CRP) levels were lower in the MSM group compared to placebo at week 16. However, the placebo group showed increased CRP levels at week 8 and 16 compared to week 4. # Significantly different from week 4, p ≤ 0.05; ‡ significantly different from placebo group, p ≤ 0.05.

Similar articles

Cited by

References

    1. Ogden C.L., Flegal K.M. Prevalence of Obesity Among Adults and Youth: United States, 2011–2014. NCHS Data Brief. 2015;131:1–8. - PubMed
    1. Fève B., Bastard J.-P. The Role of Interleukins in Insulin Resistance and Type 2 Diabetes Mellitus. Nat. Rev. Endocrinol. 2009;5:305–311. doi: 10.1038/nrendo.2009.62. - DOI - PubMed
    1. Suzuki T., Katz R., Jenny N.S., Zakai N.A., LeWinter M.M., Barzilay J.I., Cushman M. Metabolic Syndrome, Inflammation, and Incident Heart Failure in the Elderly: The Cardiovascular Health Study. Circ. Heart Fail. 2008;1:242–248. doi: 10.1161/CIRCHEARTFAILURE.108.785485. - DOI - PMC - PubMed
    1. Savini I., Catani M.V., Evangelista D., Gasperi V., Avigliano L. Obesity-Associated Oxidative Stress: Strategies Finalized to Improve Redox State. Int. J. Mol. Sci. 2013;14:10497–10538. doi: 10.3390/ijms140510497. - DOI - PMC - PubMed
    1. Fang L., Ellims A.H., Beale A.L., Taylor A.J., Murphy A., Dart A.M. Systemic Inflammation Is Associated with Myocardial Fibrosis, Diastolic Dysfunction, and Cardiac Hypertrophy in Patients with Hypertrophic Cardiomyopathy. Am. J. Transl. Res. 2017;9:5063–5073. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources